Navigo Proteins GmbH has established a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre, to advance the preclinical development of next-generation radiotheranostics using the Auger-electron emitting radioisotope Terbium (161Tb).
The synthesis of RP-1664, a highly potent, selective and bioavailable PLK4 inhibitor for the potential treatment of cancer, was recently reported by Repare Therapeutics Inc.
Prelude Therapeutics Inc. described the discovery of PRT-3789, a first-in-human, highly potent and selective SMARCA2-targeted protein degrader, for the potential treatment of cancer.
The aberrant expression of partner of NOB1 homolog (PNO1) is known to promote oncogenesis in the colorectum and the esophagus, but its involvement in ovarian cancer and the mechanisms behind it are not well known. Chinese researchers investigated the role of PNO1 in ovarian cancer development and progression in the preclinical setting.
Filamon Pty. Ltd. has described lysosomal targeting peptides (LYTAPs) acting as EGFR (HER1; erbB1) degradation inducers reported to be useful for the treatment of cancer.
Baoyuan Biomedical Technology (Hangzhou) Co. Ltd. has identified serine/threonine-protein kinase ULK inhibitors reported to be useful for the treatment of cancer.
Arcus Biosciences Inc. has disclosed mast/stem cell growth factor receptor Kit (KIT; c-Kit; CD117) inhibitors reported to be useful for the treatment of cancer, allergy, autoimmune, inflammatory, cardiovascular, metabolic, dermatological and respiratory disorders, among others.
Silexion Therapeutics Corp. has announced an expanded development plan for its next-generation siRNA candidate SIL-204. The new dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, respectively, to treat KRAS-driven pancreatic cancer.
Researchers from Tianjin Accendatech Technology Co. Ltd. and collaborators have reported the discovery of a series of novel fluorine-containing parthenolide derivatives designed for use as antitumoral compounds.
Sun Pharma Advanced Research Co. Ltd. has filed an IND application with the FDA for SBO-154 for the treatment of solid tumors. A global phase I study is planned in advanced solid tumors.
RSS
